netFormulary NHS
Coventry and Warwickshire Area Prescribing Committee

Enter drug (generic/brand) name(s)/product
or therapy area eg: hypertension
typing ‘partial words’ will enhance your search option

Useful Links

Latest APC Revisions

October 2020

September 2020


APC Newsletters

October 2020

March 2020

Prescription Request Clarification Form

Share Care Request Letter

Warwickshire North:
Shared Care Agreements - level 2

Obtain current SCA(s) from this website DO NOT save document(s) as reguarly updated

Important:APC guidance

View Chapter 4.10

Drugs used in substance dependence


Chapter 17: Primary care Antimicrobial guidance - this section is in development
Notes section
 RAG rating prescribing CNS infections Dental infections 
 ENT infections Eye infections Gastrointestinal infections
Genital Tract infections Parasitic infections Respiratory Tract infections
Skin & Soft tissue infections  Urinary Tract infections  Viral infections

Email APC office: to request APC submission forms (detail enquiry) OR to request a shared care agreement (SCA) template

Further APC information Click Here


CRCCG/WNCCG Over the Counter (OTC) Policy


News Feed

January 2021 Price Concessions: 1st update - updated 18th January  

MHRA Drug Safety Update: COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice added 08.01.21

CAS Alert: Immediate Actions In Response To Mink-Variant Sars-Cov-2 Virus In Denmark added 12.11.20

MHRA Drug Safety Update (COVID-19) June 2020 - updated 04.08.20

Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines -updated 27.05.20

CAS Alert: Covid-19 General Case Definition Change added 18.05.20

Medicines Supply information - updated 29th December

NICE COVID-19 Rapid guidelines and evidence summaries updated 19.08.20

NHS England Novel Coronavirus Alert - updated 13th March

Novel Coronavirus flowchart

NHS England Novel Coronavirus - Ibuprofen And Coronavirus (Covid-19)  updated 15th April


The Coventry & Warwickshire Formulary has been developed through wide consultation with stakeholders in both primary and secondary care which has delivered an initial version covering over 40 sections and sub-sections of the BNF. The formulary will be a dynamic list of drugs considered as the most cost-effective alternatives in each section, the decision underpinned by high grade evidence, and changes will be made as the evidence base alters and/or costs change.

Coventry & Warwickshire Prescribing Formulary - Overview
General considerations
A) Preferred, Second-line and Non-Formulary (Qualified) choices
  • The formulary has been designed to offer the prescriber sufficient evidence based and cost effective first line choices appropriate for the majority of clinical scenarios
  • Second line choices allow for specifically licensed and/or nationally guided options and together with the first line choices will give the prescriber scope to manage all but a few patients in each therapy area
  • Non-formulary (Qualified) choices are all other drugs in that BNF section which are considered unnecessary. However in rare circumstances they may be prescribed but the prescriber should justify this and record the selection in the patient record.
B) Specialist Drugs
These are important APC outputs as they guide all prescribers, in secondary and primary care, to those drugs which are considered as “specialist” and into which category they have been placed. The four categories are:  SI, SA, SC, SO  for explanation of these terms
click here
C) Liquid preparations
As a general principle licensed medicines should be used whenever possible. Where a patient has, for example, swallowing difficulties and cannot take solid dose medicines then licensed liquid/buccal/patch versions or other alternatives, for example, should be used instead. This may require a change to another product in the same class of medicine through a review of the patient's medication. When there is no alternative please consult the APC guidance on specials for alternative approaches including off label use of licensed products, e.g. dissolving solid dose versions in water, and, as a last resort, ordering unlicensed specials on prescription (See below).
APC Guideline on Specials and alternatives
D) Generic v Branded

Prescribers should always default to the generic version of the drug, and the formulary uses the approved generic names for all preferred and second-line choices, except in the following circumstances;

  • Bioavailability variation between different manufacturers version sof a drug is clinically important, e.g. theophylline, diltiazem
  • Local decision makers have approved the use of a particular brand on the grounds of cost-effectiveness, e.g. Venlalic XL®
E) National QIPP indicators
Those drugs, prescribing of which is subject to scrutiny via a national QIPP indictor, are marked with the annotation below. In these areas prescribers need to give consideration either to the choice of drug, which is reflected in the preferred options e.g. NSAIDs, or the volume of prescribing of a class of drugs, e.g. high dose inhaled corticosteroids.


   Last updated: 18/01/2021 13:44:13
    Download net formulary from Apple IOS Store  Google Play net formulary